Psilocybin Therapy Pilot Program For California Vets And First Responders, Policy Reform Hot Topic, DEA And FDA Moves On Psychedelics
DEA Pauses Hearing On Proposed Psychedelics Ban, Here’s Why
This week’s administrative hearing on the DEA’s proposed ban of two psychedelic compounds was canceled by the agency. The agency was slated to hear from experts as it seeks to classify two compounds as Schedule I drugs under the Controlled Substances Act (CSA), reported Marijuana Moment.
“As the matter before DEA is currently stayed, no hearing will commence on June 10, 2024,” according to a notice published in the Federal Register last week.
Why the cancellation? Panacea Plant Sciences (PPS) filed a complaint and request recently for injunctive relief against the agency in the U.S. District Court for the Western District of Washington. The substances in question are hallucinogens, 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4–chloroamphetamine (DOC).
See also: DEA Renews Effort To Place 2 Psychedelics In Strictest Drug Category
FDA Warns Of Mushroom Chocolate Bars That Cause Adverse Health Effects
On Friday, the Food and Drug Administration (FDA) issued an alert notifying consumers that eight people across four states experienced illnesses related to consumption of certain mushroom-containing chocolate bars, reported Green Market Report.
Those who consumed Diamond Shruumz-brand products and became ill “reported a variety of severe symptoms including seizures, central nervous …